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Background: Our previous studies have demonstrated that autophagosome-enriched vaccine (named DRibbles:
DRiPs-containing blebs) induce a potent anti-tumor efficacy in different murine tumor models, in which
DRibble-containing ubiquitinated proteins are efficient tumor-specific antigen source for the cross-presentation
after being loaded onto dendritic cells. In this study, we sought to detect whether ubiquitinated proteins
enriched from tumor cells could be used directly as a novel cancer vaccine.
Methods: The ubiquitin binding protein Vx3(A7) was used to isolate ubiquitinated proteins from EL4 and
B16-F10 tumor cells after blocking their proteasomal degradation pathway. C57BL/6 mice were vaccinated with
different doses of Ub-enriched proteins via inguinal lymph nodes or subcutaneous injection and with DRibbles,
Ub-depleted proteins and whole cell lysate as comparison groups, respectively. The lymphocytes from the
vaccinated mice were re-stimulated with inactivated tumor cells and the levels of IFN-γ in the supernatant were
detected by ELISA. Anti-tumor efficacy of Ub-enriched proteins vaccine was evaluated by monitoring tumor
growth in established tumor mice models. Graphpad Prism 5.0 was used for all statistical analysis.
Results: We found that after stimulation with inactivated tumor cells, the lymphocytes from the Ub-enriched
proteins-vaccinated mice secreted high level of IFN-γ in dose dependent manner, in which the priming
vaccination via inguinal lymph nodes injection induced higher IFN-γ level than that via subcutaneous injection.
Moreover, the level of secreted IFN-γ in the Ub-enriched proteins group was markedly higher than that in the whole cell
lysate and Ub-depleted proteins. Interestingly, the lymphocytes from mice vaccinated with Ub-enriched proteins, but
not Ub-depleted proteins and whole cell lysates, isolated from EL4 or B16-F10 tumor cells also produced an obvious
level of IFN-γ when stimulated alternately with inactivated B16-F10 or EL4 tumor cells. Furthermore, Ub-enriched
proteins vaccine showed a significant inhibitory effect on in vivo growth of homologous tumor, as well as allogeneic
tumor, compared with Ub-depleted proteins and tumor cell lysate. Tumor growth was regressed after three times of
vaccination with Ub-enriched proteins in contrast to other groups.
Conclusion: These results indicated that Ub-enriched proteins isolated from tumor cells may have a potential as a
potent vaccine for immunotherapy against cancer.
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Cross-presentation is the process by which the antigens
from “antigen-donor cell (ADC)” are captured, processed,
and then presented to antigen-specific T cells by host pro-
fessional antigen-presenting cells (pAPCs) [1-3]. It is well
established that cross-presentation of tumor antigens de-
rived from tumor cell as antigen-donor cell plays a pivotal
role in the initiation and development of cytotoxic T
lymphocytes (CD8+ CTL) immune response to tumor-
associated antigens (TAAs), including self or mutated self-
antigens derived from tumor cells [1,4].
There are two major pathways for TAAs proteolysis in
the tumor cells. The short-lived proteins (SLiPs), including
the defective ribosomal products (DRiPs), are ubiquitinated
and degraded by proteasomes [5,6], whereas the long-lived
proteins are mostly degraded by the lysosomes through the
autophagy pathway [7,8]. It is generally believed that the
proteasome-mediated protein degradation pathway plays
an important role in providing peptides for MHC-I re-
stricted antigen presentation in antigen-donor cells (direct
presentation), while the long-lived protein but not short-
lived proteins are normally cross-presented by host pAPCs.
Under abnormal physiological conditions, i.e., when either
pathway is defective, the degradation of proteins is shunted
from one pathway to the other to protect cell survival [9].
Our previous studies have demonstrated that with induc-
tion of autophagy and inhibition of lysosomal/proteosomal
activity, a broad spectrum of cellular antigens, including
long-lived proteins, short-lived proteins, as well as defective
ribosomal products, are sequestered in autophagosomes
[9]. We refer these autophagosome-enriched, defective
ribosomal products-containing blebs as to DRibbles. We
also documented that DRibbles derived from tumor cells
are efficient TAAs carriers for cross-presentation by den-
dretic cells, by which DRibble vaccine can stimulate dra-
matic T-cell activation, leading to an anti-tumor efficacy in
different tumor models such as melanomas, lung carcin-
omas, breast carcinomas and liver cancer [10-12].
It’s believed that DRibble can serve as a vessel to ferry a
broad spectrum of tumor antigens to pAPCs for efficient
cross-presentation, and the anti-tumor efficacy induced by
DRibbles is mainly depending on its content of ubiquiti-
nated TAAs [9]. In this study, we sought to isolate ubiquiti-
nated proteins (Ub-Ps), including short-lived proteins, as
well as defective ribosomal products, from tumor cells after
inhibition of their proteasome-mediated protein degrad-
ation pathway, and detect whether Ub-Ps could be used
directly as a novel cancer vaccine to induce a specific tumor
immune response.
Materials and methods
Cell culture and reagents
The following two cancer cell lines, lymphoma EL4 and
melanoma B16-F10 were cultured in PRMI 1640 andDMEM medium respectively supplemented with 10%
heat-inactivated fetal bovine serum, 100 U/ml penicillin,
0.1 mg/ml streptomycin (Beyotime Institute of Biotech-
nology, Haimen, China) in a humidified incubator in 5%
CO2 at 37°C. pUbiG101-Vx3(A7)-eGFP plasmid was
kindly gifted by Prof. Hong-Ming Hu (Providence Can-
cer Center, Providence Portland Medical Center, USA).
Ni-NTA agarose beads were purchased from MCLAB
Company (NINTA-200).
Mice
C57BL/6 female mice were purchased from the Compara-
tive Medicine Center, Yangzhou University (Yangzhou,
China). All mice were bred and maintained in a specific
pathogen-free condition. All experimental protocols were
approved by the Institutional Animal Care and Use Com-
mittee of Southeast University.
Tumor cell lysate preparation
Proteasome degradation pathway in tumor cells was
blocked by adding 100 nM Bortezomib (Velcade) in
complete medium for 5 hours in a 5% CO2 incubator at
37°C. The treated cells were centrifuged (1200 rpm/4°C-
SORVALL ST 16R) for 10 minutes, and washed three
times by PBS. The precipitated cells were then lysed
with a Tris-base lysis buffer containing 20 mM Tris-
base, 137 mM NaCl, 1% NP-40, 20 mM EDTA and pro-
tease/phosphatase inhibitor cocktail for 30 minutes. Cell
lysates were collected after centrifuge (14000 rpm/4°C-
Eppendorf AG 5417R) for 15 minutes [13]. Protein con-
centration was quantified by BCA protein assay Kit
according to the manufacturer’s protocol (Beyotime In-
stitute of Biotechnology).
Vx3(A7) protein expression and purification
pUbiG101-Vx3(A7)-eGFP expressing vector was cloned
into E. coli DH5-α competent cells (invitrogen). Cells
were grown in LB medium for 3 hours at 37°C (until
OD550 = 0.5). After that, 1 M IPTG was added for
16 hrs at 15°C. Cells were harvested and centrifuged
(8000 rpm/4°C-himac CR 21G) for 15 minutes. Pellet
was re-suspended in sodium-phosphate buffer supplied
with 0.001 mg/ml lysozyme and kept in ice for 30 mi-
nutes. After sonication of the solution using six 10-
seconds bursts at high intensity, cellular debris in the
lysate were pelleted down through centrifugation
(15000 rpm/4°C-himac CR 21G) for 10 minutes. Super-
natant was collected as ‘Bacterial cell lysate’ sample.
Vx3(A7) protein was purified using Ni-NTA agarose
beads. Briefly, beads were washed three times by native
binding buffer after washing with sterile distilled water.
The beads were incubated with the previous Bacterial cell
lysate for 1 hour at 4°C with gentle agitation. Unbound
proteins were collected as ‘Flowing fraction’ followed by
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and collected as ‘Washing fraction’. The bounded proteins
were eluted by native elution buffer (0.25 M Imidazole) as
‘Elution fraction’. The purity of eluted proteins was tested
by SDS PAGE. The endotoxin level of proteins used for
vaccination was < 0.2 EU/mg.
Ubiquitinated proteins purification
Ni-NTA agarose beads were washed one time with ster-
ile distilled water followed by three washing times with
the native binding buffer and then were incubated with
the purified Vx3(A7) protein for 1 hour at 4°C. Agarose
beads bounded with Vx3(A7) protein were washed three
times by native washing buffer and then were incubated
with the prepared whole tumor cell lysate for 24 hours
at 4°C. Unbound fractions were collected and beads
were washed three times by native washing buffer. Vx3
(A7)-Ubiquitinated proteins complex was eluted using
native elution buffer (3 M Imidazole). Eluted proteins
were tested by western blot.
Western blotting
The samples were resolved by 12.5% SDS-PAGE (Invi-
trogen) after mixing with SDS-PAGE loading buffer and
boiling for 5 minutes. Proteins were transferred to a
nitrocellulose membrane and diluted in blocking buffer
(5% dry milk) for 1 hour, and then incubated separately
with mouse anti-ubiquitin antibody (1:500, Sigma) and
anti-K63 antibody (1:500, Enzo) overnight. Secondary
antibody (1:5000, Pierce) was added for 1 hour. Mem-
brane was exposed using the cassette in dark room.
DRibbles preparation
Tumor cells were treated with 100 nM Rapamycin (Enzo
Life Sciences, BML-A275-0005), 100 nM Bortezomib,
and 10 mM ammonium chloride in complete medium
for 18–24 hours in a 5% CO2 incubator at 37°C. The
cells and the supernatant were harvested and spun at
(1300 rpm-SORVALL ST 16R). The supernatant was
then spun at (30,000 rpm/4°C-himac CR 21G) to harvest
the DRibbles. The total concentration of DRibbles pro-
teins was measured by Bradford assay [14].
Detection of immune responses and immunotherapy
experiments
C57BL/6 female mice were vaccinated three times with
two days of intervals via two different routes of adminis-
tration, subcutaneous injection (s.c.) or inguinal lymph
nodes injection (i.n.) and with different doses (0, 30, 100
and 300 μg total protein / mouse) of whole cell lysate,
Ub-depleted proteins, Ub-enriched proteins or DRibbles,
respectively. One week after last vaccination, the lym-
phocytes collected from spleen and lymph node of vacci-
nated mice were added to 48-well plates (2.5 × 106 cells/well) and re-stimulated for three days, in a 5:1 ratio, with
EL4 or B16-F10 tumor cells pretreated with colchicine
(1 μg/ml) for 2 hours. In addition, anti mouse CD3 anti-
body (BD Biosciences) was used as a positive control to
induce the lymphocytes activation and IFN-γ secretion
following the company protocol. Briefly, 48-well plates
were coated overnight at 4°C with 10 μg/mL of anti-
mouse CD3 prepared in sterile PBS. Then, the plates
were washed three times with sterile PBS to remove
non-bound soluble antibody and lymphocytes from the
vaccinated mice were added. The level of IFN-γ in the
cell culture supernatant was detected by ELISA. IFN-γ
in the serum of the vaccinated mice was also measured
by ELISA, whole blood were collected and kept for
30 minutes at room temperature to allow the clot forma-
tion. Then, different group’s sera were collected by re-
frigerated centrifuge (1300 rpm/4°C-Eppendorf AG
5417R) for 10 minutes.
To evaluate the antitumor efficacy of Ub-enriched pro-
teins, C57BL/6 mice were s.c. injected with 1 × 106 EL4
or B16-F10 tumor cells on day 0. Subsequently, Ub-
enriched proteins, Ub-depleted proteins, whole cell ly-
sates or PBS and Vx3(A7) protein (as control) were
injected (i.n. s.c s.c.) into both flanks of tumor-bearing
mice respectively on days 7, 9, and 11. Tumor growth
was assessed by measuring the perpendicular diameters.Intracellular staining
Lymphocytes collected from spleen and lymph node of
relevant vaccinated mice were cultured with inactivated
B16-F10 tumor cells for 48 hours and in the presence of
brefeldin A (10 μg/ml) for last 6 hours at 37°C in 5%
CO2. Later, cells were washed in PBS supplemented with
3% fetal bovine serum (FBS) and blocked for nonspecific
binding in 30% FBS for 30 min. Surface staining was per-
formed using FITC-conjugated anti-CD4 and APC-
conjugated anti-CD8 followed by intracellular staining
with Cytofix/Cytoperm kit (eBioscience) in accordance
with the manufacturer's instructions. Briefly, cells were
fixed and permeabilized with Cytofix/Cytoperm solution
for 1 hour on ice followed by washing in Perm/Wash so-
lution. Next, cells were stained for 30 min on ice with
PE-conjugated anti-IFN-γ. Finally, cells were resus-
pended in PBS buffer and analyzed by flow cytometry
(FACSCalibur-BD Biosciences).Statistical analysis
Graphpad Prism 5.0 (Graphpad software, San Diego,
CA) was used for all statistical analysis. The mean ± SD.
was determined for each group in the individual experi-
ments. The Student t-test was used to determine the sig-
nificance of differences between vaccinated and control
groups. P-values < 0.01 were significant.
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Ubiquitinated proteins are effectively isolated from tumor
cell lysate by Vx3(A7) protein
We previously demonstrated that proteasome inhibition
resulted in accumulation of ubiquitinated proteins,
which were further shunted into autophagosomes after
treatment with autophagy inducer, the following vaccin-
ation improved crosspresentation of the ubiquitinated
proteins -containing autophagosomes [10,12,15]. Here,
we used a ubiquitin binding protein Vx3 (A7) to isolate
ubiquitinated proteins from tumor cells after blocking
their proteasomal degradation pathway and sought to
detect whether enriched ubiquitinated proteins could be
directly used as a novel cancer vaccine (Figure 1A).
Vx3(A7) protein is composed from multiple tandem
ubiquitin interacting motifs (tUIMs) with structured
linker regions that bind with high-affinity to Lys63-poly
ubiquitins [16]. Firstly, we used Ni-NTA agarose beads
to purify his-Vx3(A7)-eGFP fusion protein expressed by
E. coli DH5α that already transformed with pUbiG101-
Vx3(A7)-eGFP recombinant plasmid. We found that the
‘Elution fraction’ was obviously greener than bacterialFigure 1 Ubiquitinated proteins were effectively isolated by Vx3(A7) protei
binding with His-Vx3(A7)-eGFP protein conjugated with Ni-NTA agarose be
bacterial cell lysate, flowing fraction, washing fraction and elution fraction w
detect the whole bacterial cell lysate proteins (lane 1) and the His-Vx3(A7)-
Beads. (D) EL4 and B16-F10 tumor cells were treated with bortezomib (200 nM
buffer. Ni-NTA agarose beads conjugated with Vx3(A7) proteins were used to
(EL4, lane 2) and (B16-F10, lane 6), unbound (lane 3,7), washed (lane 4,8) and e
Blot analysis for ubiquitin proteins and K63 proteins in lysates (lane 1), unboun
EL4 (E) and B16-F10 (F) tumor cells using anti-ubiquitin and anti-K63 monoclocell lysate, whereas the green color has not appeared in
the ‘Flowing fraction’ and ‘Washing fraction’ (Figure 1B).
These results were confirmed by SDS–PAGE analysis
which showed that his-Vx3(A7)-eGFP fusion protein was
successfully purified with an apparent molecular mass of
37 kDa (Figure 1C, lane M and 2) compared with bacter-
ial cell lysate which revealed the presence of several pro-
teins (Figure 1C, lane 1).
Next, we prepared lysates from EL4 and B16-F10
tumor cells in which proteasome function was inhibited
by bortezomib, Ni-NTA agarose beads conjugated with
the purified Vx3(A7) protein were used to isolate Ub-Ps.
SDS-PAGE analysis revealed that the number of bands
in the elution fractions were lower than those in the
whole cell lysates and unbound fractions, whereas, few
protein bands were detected in the washing fractions
(Figure 1D). The western blot analysis using anti-ubiquitin
antibody and anti-K63 antibody (Figure 1E and F) showed
that the level of ubiquitin and K63 Ub protein in the un-
bound fractions (lane 2) and washed fractions (lane 3) was
obviously lower than that in the eluted samples with same
total protein concentration (lane 4). Moreover, muchn. (A) A schematic diagram of Ubiquitinated proteins purification by
ads. (B) Ni-NTA agarose beads were used to purify Vx3(A7) protein,
ere collected and observed. (C) 12.5% SDS-PAGE was performed to
eGFP fusion proteins (lane 2) which purified using Ni-NTA agarose
) and NH4Cl (10 mM). Whole cell lysates were prepared using tis-HCl lysis
isolate ubiquitinated proteins. Twenty micrograms of whole cell lysate
luted fractions (lane 5,9) were loaded on SDS PAGE gel. (E, F) Western
d (lane 2), washed (lane 3) and eluted (lane 4) fractions harvested from
nal antibodies, respectively.
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in the eluted samples from both EL4 and B16-F10 cells
(lane 4) compared with whole cell lyaste (lane 1). These
data indicated that Vx3(A7) protein is an effective tool to
enrich ubiquitinated proteins (Ub-enriched proteins) from
tumor cell lysate.
Ub-enriched proteins induce tumor-specific immune
response
To investigate whether Ub-enriched proteins could in-
duce tumor specific immune response, C57BL/6 mice
were immunized with different doses (0, 30, 100 and
300 μg total protein / mouse- 3 mice/group) of Ub-
enriched proteins collected from EL4 tumor cells via
two different routes of administration, subcutaneous
(s.c.) and intr-anodal (i.n.), respectively. On day 10 after
last vaccination, the lymphocytes collected from spleen
and lymph node of vaccinated mice were re-stimulated
with inactivated EL4 tumor cells for 72 hours or cul-
tured without stimulation (CM) (αCD3 mAb stimulation
was used as a positive control), secreted IFN-γ was de-
tected by ELISA analyses. As expected, vaccination with
Ub-enriched proteins via both subcutaneous (s.c.) and
intr-anodal (i.n.) injections induced specific immune re-
sponse against EL4 tumor cells in a dose-dependent
manner without a significant difference between 100 and
300 μg (Figure 2A and B). However, the lymphocytes
from mice that primed with i.n. administration secreted
a significantly higher level of IFN-γ than that from mice
which primed with s.c. administration with the same
dose of Ub-enriched proteins (Figure 2A-C). As shown
in Figure 2C, the production of IFN-γ by lymphocytes
from mice vaccinated s.c. with 100 μg of Ub-enrichedFigure 2 Ub-enriched proteins induced a tumor-specific immune response
30, 100 and 300 μg by Ub-enriched proteins isolated from EL4 whole cell l
injections (B) with two days interval. On day 10 after last vaccinations, lympho
EL4 tumor cells that already inactivated by 10 nM of colchicine or without stim
IFN-γ produced by the responder cells was determined after 72 h by ELISA. (C
different route of vaccination (s.c. and i.n.) respectively using 100 μg of Ub-en
experiments results.proteins was markedly lower than that which vaccinated
i.n with the same dose. These results indicated that Ub-
enriched proteins were able to induce a tumor specific
immune response in dose dependent manner. The prim-
ing via i.n. administration induced a stronger immune
response than that via s.c. administration, Based on
these findings, 100 μg Ub-enriched proteins via i.n. ad-
ministration was used as a preferable strategy in the next
experiments.
Ub-enriched proteins elicit a stronger tumor specific
immune response than whole tumor cell lysate and
Ub-depleted proteins
In order to investigate whether Ub-enriched proteins
could induce a stronger tumor specific immune response
than whole tumor lysate or/and Ub-depleted proteins,
we vaccinated four groups (3 mice/group) of C57BL/6
mice with Ub-enriched proteins, Ub-depleted proteins
and tumor cell lysate prepared from B16-F10 and EL4
tumor cells, respectively. Injection with PBS was used as
a negative control. The Blood serum and lymphocytes
were collected from the vaccinated mice. Lymphocytes
were re-stimulated for 72 hours with inactivated B16-
F10 and EL4 tumor cells and with or without αCD3
mAb as a positive or negative control. The levels of IFN-
γ in the serum and the culture supernatant were moni-
tored by ELISA.
The results showed that IFN-γ level in the serum of
mice vaccinated with Ub-enriched proteins from EL4
(Figure 3A) and B16-F10 tumor cells (Figure 3B) was
higher than that in the serum of mice vaccinated with
Ub-depleted proteins, whole tumor lysate or PBS. Fur-
thermore, after stimulation with the relevant inactivated. C57/BL16 mice (3 mice/group) were vaccinated respectively with 0,
ysate via triple s.c. injections (A) or i.n. priming injection plus twice s.c.
cytes were collected from spleen and lymph nodes and re-stimulated by
ulation (CM). α-CD3-Ab stimulation was used as positive control. The
) Comparing between the immune response resulted by previous two
riched proteins. Data are representative of three independent
Figure 3 Tumor specific immune response resulted by Whole tumor cell lysate, Ub-depleted proteins and Ub-enriched proteins. C57/BL6 mice (3
mice/group) were primed by 30 μg i.n and twice 100 μg s.c vaccination with two days of interval by whole cell lysate, Ub-depleted proteins and
Ub-enriched proteins from EL4 tumor cells (A, C) and B16-F10 tumor cells (B, D). On day 10 after last vaccinations, blood was collected and the
IFN-γ levels in the sera were detected by ELISA (A, B). Lymphocytes were collected from spleen and lymph nodes and re-stimulated by EL4 and
B16-F10 tumor cells that already inactivated by 10 nM of colchicine or without stimulation (CM). α-CD3-Ab stimulation was used as positive
control. The IFN-γ produced by the responder cells was determined after 72 h by ELISA (C, D). Data are representative of three independent
experiments results. (E) Flow cytometric analysis of intracellular IFN-γ synthesized by CD4+ T cells (upper panel) and CD8+ T cells (lower panel) in
the lymphocytes from mice vaccinated with PBS and whole cell lysate, Ub-depleted proteins and Ub-enriched proteins from B16-F10 tumor cells
and restimulated with inactivated B16-F10tumor cells. Numbers within quadrants represent the percentage of positive cells for IFN-γ within the
gate for relevant lymphocytes.
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Ub-enriched proteins vaccinated mice produced a sig-
nificantly higher level of IFN-γ than that from Ub-
depleted proteins and whole tumor lysate vaccinated
mice (Figure 3C, D). Interestingly, the lymphocytes from
B16-F10-derived Ub-enriched proteins vaccinated mice
produced a significantly higher level of IFN-γ than that
from Ub-depleted proteins and whole tumor lysate vac-
cinated mice when stimulated with inactivated EL4
tumor cells (Figure 3C), similar results were observed
when the lymphocytes from EL4-derived Ub-enriched
proteins vaccinated mice were re-stimulated with inacti-
vated B16-F10 tumor cells (Figure 3D). Intracellular
staining detection showed that, after stimulation with
B16-F10 tumor cells in vitro, the percentage of IFN-γ+
CD4+ T cells and IFN-γ+ CD8+ T cells from mice vacci-
nated with B16-F10-derived Ub-enriched proteins was
higher than that from mice that vaccinated with tumor
cell lysate, Ub-depleted proteins or PBS (Figure 3E). To-
gether, these results indicated that Ub-enriched proteins
vaccine is more efficient to induce a specific tumor im-
mune response than Ub-depleted proteins and tumor
cell lysate, supporting it as a tumor vaccine candidate.
Both Ub-enriched proteins and DRibbles induce a strong
tumor specific immune response
To prove the ability of Ub-enriched proteins to induce a
tumor specific immune response same as DRibbles,
three groups (3 mice/group) of C57BL/6 mice were vac-
cinated three times (i.n., s.c, s.c.) with Ub-enriched pro-
teins and DRibbles from EL4, B16-F10 tumor cells and
PBS as negative control respectively. Ten days after the
last vaccination, lymphocytes were collected and stimu-
lated with inactivated EL4 or B16-F10 tumor cells forFigure 4 Tumor specific immune response induced by Ub-enriched prot
30 μg i.n and twice 100 μg s.c vaccination with two days of interval by U
A) and B16-F10 cells B). Ten days after the last vaccination, Both lymph n
cell suspensions and re-stimulated by EL4 and B16 tumor cells that already in
used as positive control. The secreted IFN-γ level was determined after 72 h b
results.72 hours or without stimulation (CM). ELISA detection
showed that there was no detectable difference in the level
of IFN-γ secreted by the lymphocytes from DRibbles and
Ub-enriched proteins vaccinated mice; both of them in-
duced a production of a high level of IFN-γ compared
with the negative control mice (Figure 4A, B). These data
demonstrated that Ub-enriched proteins and DRibbles
have a similar ability to induce a strong tumor specific im-
mune response.
Ub-enriched proteins has a potent therapeutic efficacy on
established tumor model
We evaluated the antitumor efficacy of the Ub-enriched
proteins vaccinations in both EL4 and B16-F10 murine
tumor models. In the EL4 model, twenty C57BL/6 mice
were s.c. injected by 1 × 106 of EL4 tumor cells. On day
seven, tumor bearing mice were divided randomly into
four groups and received single i.n. injection on day 7
and twice s.c. injections on day 9 and 11 with tumor cell
lysate, Ub-depleted proteins, Ub-enriched proteins and
PBS as a control. We observed that vaccination with
Ub-enriched proteins significantly inhibited EL4 tumor
growth compared with other three groups. Four out of
five treated mice by Ub-enriched proteins rendered tumor
free and survived more than 40 days (Figure 5A, B). We
also found that Ub-enriched proteins prolonged the me-
dian survival time of the mice (more than 56 days for the
Ub-enriched proteins group vs. 25 days for tumor cell
lysate and 22 days for Ub-epleted proteins and PBS)
(Figure 5C).
To further detect whether Ub-enriched proteins vac-
cination could not only inhibit the growth of homolo-
gous tumor, but also inhibit the nonhomologous tumor
growth, we established two murine tumor models by s.c.eins and DRibbles. C57/BL6 mice (3 mice/group) were primed by
b-enriched proteins and Dribbles respectively isolate from EL4 cells
odes and spleen of the mice were collected, processed into single
activated by 10 nM of colchicines or without stimulation (CM). α -CD3-Ab
y ELISA. Data are representative of three independent experiments
Figure 5 Anti-tumor efficacy of Ub-enriched proteins vaccine in EL4 tumor model. The anti-tumor efficacy of Ub-enriched protein vaccine was
evaluated in EL4 murine models. (A) Twenty C57BL/6 mice were injected s.c. with 1 × 106 EL4 tumor cells. Seven days later, mice established
tumors were divided randomly into four groups of 5 animals each with comparable mean tumor sizes. One group was then left untreated; other
three were received single i.n. and twice s.c. vaccination on days 7, 9 and 11 with EL4 cell lysate, Ub-depleted proteins and Ub-enriched proteins
respectively. Tumor growth was measured three times a week. (B) Representing the tumor size of individual mice for each group. (C) The percent
survival time of four EL4 tumor model groups. This data is from two experiments with similar results.
Aldarouish et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:34 Page 8 of 12injection of 1 × 106 EL4 or B16-F10 into C57BL/6 mice
(20 mice/established tumor model). On day seven, EL4
or B16-F10 tumor bearing mice were divided randomly
into eight groups and received i.n. Priming vaccination
on day 7 and twice s.c. vaccinations on day 9 and 11
with Ub-enriched proteins derived from EL4 cells and
B16-F10 cells, respectively. Vaccination with PBS and
Vx3(A7) protein was used as control.
As expected, EL4 tumor growth in 3 out of 5 treated
mice with EL4-derived Ub-enriched proteins were
regressed and rendered tumor free and survived more than
56 days compared with Vx3(A7) and untreated PBS con-
trols. Interestingly, we found that vaccinations with B16-
F10-derived Ub-enriched proteins significantly suppressedEL4 tumor growth and prolong the median survival time to
34 days compared with 26 days in the Vx3(A7) group and
22 untreated PBS control group (Figure 6A-C). Similar
results were observed in the B16-F10 tumor model
(Figure 6D-F), in which both vaccinations with B16-F10
and EL4 tumor cell-derived Ub-enriched proteins re-
markably inhibited B16-F10 tumor growth and signifi-
cantly improved survival and prolonged the median
survival time to more than 56 days vs 42 days compared
with 26 and 22 days in the Vx3(A7) and untreated PBS
control groups respectively.
Moreover, 4 out of 5 treated mice with Ub-enriched
proteins derived from B16-F10 cells were rendered
tumor free. These results clearly demonstrated that Ub-
Figure 6 (See legend on next page.)
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Figure 6 Anti-tumor efficacy and Cross Action of Ub-enriched proteins Vaccine in EL4 and B16-F10 tumor models. C57BL/6 mice were injected s.c. with
1 × 106 EL4 tumor cells (A-C) and 1 × 106 B16-F10 tumor cells (D-F). Seven days later, mice established tumors were divided randomly into groups of 5
animals each with comparable mean tumor sizes. Two groups were then left untreated; other four were primed with single i.n. and twice s.c. vaccination
n days 7, 9 and 11 with Vx3(A7) protein, Ub-depleted proteins and Ub-enriched proteins isolated from EL4 and B16 tumor cells respectively
and separately. The tumor growth was measured three times a week (A, B, D, E). (A, D) Representing the tumor size of individual mice for each group.
(C, F) The percent survival time of EL4 and B16 tumor models groups respectively. This data is from two experiments with similar results.
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cacy on homologous tumor and expand a cross-protection
on nonhomologous tumor.
Discussion
Tumor antigen can be directly presented by tumor cells
themselves or cross-presented by pAPCs. Both cross-
presentation and direct presentation of tumor antigen
have an important role in the induction of tumor-
protective cytotoxic T lymphocytes immunity. Most of
tumor cells, because of lacking costimulatory molecules,
cannot induce naïve CD8+ T cells response by direct
presentation and therefore cannot elicit protective anti-
tumor immunity. In contrast, it has been documented
that tumor antigen cross presentation by pAPCs is crit-
ical to induce antitumor immunity because pAPCs are
able to deliver the antigen signal by MHC molecules
and express a high level of co-stimulatory molecules
signals simultaneously to the T cell for activation to
occur [17-19].
Our previous studies have demonstrated that DRibbles
isolated from tumor cells after proteasome inhibition,
which lead to the accumulation of defective ribosomal
products, short-lived proteins and their immunogenic frag-
ments are efficient antigen carriers for cross-presentation
by dendretic cells. DRibbles efficiently cross-prime antigen-
specific naïve CD8+ and CD4+ Tcells; and DRibbles vaccine
induce an anti-tumor efficacy in different tumor models
such as melanomas, lung carcinomas and breast carcin-
omas [11,13,20]. We found that the ubiquitinated TAAs are
critical components of DRibbles which induce the antitu-
mor efficacy. Moreover, it’s believed that much more ubi-
quitinated proteins could be collected from tumor cell
lysates (especially after proteasome inhibition) comparing
with DRibbles. So that, we hypothesized that the ubiquiti-
nated proteins enriched from tumor cells after blocking
their proteasomal degradation pathway could be an efficient
tumor-specific antigen source for the cross-presentation.
To confirm this determination, we prepared a ubiquitin
binding protein Vx3(A7) in order to isolate the Ub-Ps from
EL4 and B16-F10 tumor cells as antigen donor cells. The
tumor specific immune response and antitumor efficacy re-
sulted by the cross-presentation of Ub-Ps were assessed
using EL4 and B16-F10 tumor models.
The proteasome is a large protein complex mediates
the degradation of polyubiquitinated (abnormal) proteins[21]. Ubiquitin (Ub) is an 8.5-kDa polypeptide molecule
tags misfolded or damaged intracellular proteins for deg-
radation by ubiquitin–proteasome system [22,23]. The
degradation of ubiquitinated short-lived proteins, includ-
ing defective ribosomal products is catalyzed via the
ubiquitin–proteasome system (UPS) espically in 26S
proteasome sub-unit [9,24]. UBDs (ubiquitin-binding
domains) are a group of modular proteins that bind
non-covalently to Ub. Two main UBDs were identified,
the UBA domain (ubiquitin-associated domain) and the
UIM (ubiquitin-interacting motif ). The UBA domain
family is compact three-helical bundles. It is classified
into four different groups according to ubiquitin-binding
properties [25,26]. p62 (SQSTM1) is the well known ex-
ample of UBA family. Its main action is recruiting Ub-Ps
to the endosomes [27,28]. The UIM is a sequence motif
which was first described in the 26S proteasome subunit
PSD4/RPN-10 that is known to recognize ubiquitin
[29,30]. S5a/Rpn10 is a subunit of the 26S proteasome
and exists in the cytosol freely. It binds poly-Ub chains
via its two Ub-UIMs [31]. Ubiquitin molecule has an
ability to modify the target proteins by two different
mechanisms, monoubiquitination or polyubiquitination
[32,33]. Ubiquitin can be linked together through their
surface lysine (K) residues (K6, K11, K27, K29, K33 and
K63), forming poly-Ub chains of different lengths and
shapes [34]. Few studies reported that Lys63-linked ubi-
quitin chains degradation is a proteasome dependent
[35,36]. Whereas, many studies documented that Lys63-
linked polyubiquitination has a destructive fate for its
substrate through through a proteasome independent
mechanism termed autophagy by which autophagasome
is formed and fused with lysosomes to degrade the se-
questered contents [37] In conclusion, Lys63-polyUb
have non-proteasomal roles in DNA repair, autophagy
and organelle clearance, endocytosi, and inflammation
signaling [38,39].
Vx3(A7) protein is composed from multiple tandem
Ubiquitin Interacting Motifs (tUIMs) with structured
linker regions that bind with high-affinity to Lys63-
polyUb. The main purpose of this protein is tracking the
linkage-specific polyUb signals in yeast and mammalian
cells and exploring their functions. Their specificity was
determined both in vitro and in vivo [17]. Ub-Ps could be
purified by different methods such as proteomic strat-
egy combining of immunoprecipitation [40], or using a
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quitin binding entities (TUBEs) [41]. In this study, we
have confirmed that Vx3(A7) protein is an effective tool
to enrich Ub-Ps from whole tumor cell lysate compared
with other kinds of UBD proteins such as TUBEs (data
not shown).
Our results showed that high concentration of Ub-Ps
was purified from both EL4 and B16-F10 cell lysate
using a native condition. This finding showed that Vx3
(A7) protein is an excellent choice to enrich abundant
level of Ub-Ps from cell lysate.
Our data refer to the ability of Ub-enriched proteins
to induce a strong tumor specific immune response.
More importantly, we found that the level of this re-
sponse is increased dramatically by increasing the vac-
cine dose. Furthermore, our results clearly showed that
the route of vaccination play a critical role in the indu-
cing of tumor immune response, by which inguinal
lymph nodes injection (i.n.) vaccination significantly in-
duced a stronger immune response than subcutaneous
vaccination.
Many studies reported that Inactivated tumor cells or
tumor cell lysates are used as cancer immunotherapy
[42,43], but it’s important to note that the majority of
defective ribosomal products and short-lived proteins
are not contained in inactivated whole tumor cells or
tumor cell lysates vaccines due to rapid degradation. In
this study we found that Ub-enriched proteins could in-
duce higher immune response than whole tumor cell
lysate and Ub-depleted proteins. Our findings also
proved that Ub-enriched proteins and Dribbles have the
same ability to induce a specific tumor immune re-
sponse. Collectively the data points that Ub-Ps are im-
portant tumor specific antigens. One major advantage of
our novel vaccine is the enrichment of higher concentra-
tion of ubiquitinated proteins from tumor cells lyaste
than Dribbles. Moreover, isolation of ubiquitinated pro-
teins from cell lysate is easier and faster than DRibbles.
Our previous results which demonstrated the anti-
tumor efficacy of DRibbles prompted us to test our new
therapeutic vaccine in murine lymphoma and melanoma
tumor models. This study showed that vaccination with
Ub-enriched proteins derived from EL4 or B16-F10 cells
seven days after tumor establishment significantly inhib-
ited EL4 and B16-F10 tumor growth respectively
compared to whole cell lysate, Ub-depleted proteins and
un-vaccinated group. Interestingly, dramatic regression
and cure of established tumors were observed in 80% of
the tumor bearing mice which vaccinated with Ub-
enriched proteins. More importantly, our results showed
that Ub-enriched proteins enriched from tumor cells not
only have an anti-tumor efficacy in the homologous
tumor but they also have the ability to delay the tumor
growth and prolong the survival time of nonhomologoustumor. These results support a novel strategy for devel-
oping a tumor immunotherapy, and support further
studies to test the efficacy of our vaccine in treating hu-
man tumors.
Conclusion
These results support a novel strategy for developing a
tumor immunotherapy depending on Ub-enriched pro-
teins, and support further studies to test the efficacy of
our vaccine in clinical trials.
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